Partners & Investors

Our Partners

In October 2017, Harpoon entered into an immuno-oncology research collaboration with AbbVie to advance our next-generation cancer immunotherapies. The goal of the collaboration is to combine the strength of Harpoon’s TriTAC platform with AbbVie’s novel T cell receptor targets to create the next wave of T cell therapeutics for cancer patients. The collaboration reflects our shared commitment to developing immunotherapies beyond checkpoint inhibitors.

Our Investors

Harpoon Therapeutics is backed by world-class life science investors, including MPM Capital, which initially seeded the company in 2015, Arix Biosciences, New Leaf Venture Partners, and Taiho Ventures.

mpm logo

arix bioscience logo

new leaf ventures logo

taiho ventures logo

OIM logo